Pathologic prognostic factors in Barrett's-associated adenocarcinoma: A follow-up study of 96 patients

Cancer

Volumn 85, Issue 3, 1999, Pages 520-528

  Torres, Carlos ^a   Turner, Jerrold R ^a   Wang, Helen H ^b   Richards, William ^a   Sugarbaker, David ^a   Shahsafaei, Ali ^a   Odze, Robert D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Chemotherapy; Prognosis; Radiotherapy; Squamous cell carcinoma

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0033083140     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990201)85:3<520::AID-CNCR2>3.3.CO;2-C     Document Type: Article

References (40)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophageal and gastric cardia. JAMA 1991;265:1287-98.
2. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994;21:403-10.
3. Cameron AS, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-6.
4. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol 1992;23:475-6.
5. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993;43:7-26.
6. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270:1320.
7. Yacoub L, Goldman H, Odze RO. Transforming growth factor -α, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol 1997;10:105-12.
8. Paraf F, Flejou J, Pignon J, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 1995;19:183-91.
9. Klimstra DS. Pathologic prognostic factors in esophageal carcinoma. Semin Oncol 1994;21:425-30.
10. Hermanek RP, Henson DE, Hutter RV, Sobin LH. International Union against Cancer: TNM supplement 1993. New York: Springer-Verlag, 1993:119-20.
11. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours: International Union Against Cancer. 5th edition. Berlin: John Wiley and Sons, 1997.
12. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-7.
13. Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, Baue AE. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg 1995;59:1085-91.
14. Kelsen DP, Ginsberg R, Qian L, Gunderson L, Mortimer J, Estes N, et al. Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: a preliminary report of intergroup study. Proc Am Soc Clin Oncol 1997(16):276A.
15. Urba S, Orringer M, Turrisi, Whyte R, lannettoni M, Forastiere A. A randomized trial comparing surgery (S) to preoperative concomitant chemoradiation plus surgery in patients (pts) with resectable esophageal cancer (CA): updated analysis. Proc Am Soc Clin Oncol 1997;(16):277A.
16. Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992;10(7):1037-43.
17. Harrison JC, Patrick JD, El-Zeky F, Vander Swaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994;25(5):498-505.
18. Hermanek P, Sobin LH, Fleming ID. What do we need beyond TNM? Cancer 1996;77(5):815-7.
19. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72(10):3131-5.
20. Daly JM, Karnell LH, Menck HR. National Cancer Data Base Report on esophageal carcinoma. Cancer 1996;78(8):1820-7.
21. Lerut T, Coosemans W, Van Raemdonck, Dillemans B, Deleyn P, Marnette JM, et al. Surgical treatment of Barrett's carcinoma. J Thora Cardiovasc Surg 1994;107(4):1059-66.
22. Streitz JM, Ellis FH, Gibb SP, Balogh K, Watkins E. Adenocarcinoma in Barrett's esophagus: a clinicopathologic study of 65 cases. Ann Surg 1991;213(2):122-5.
23. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbec N, Becker K, et al. Prognostic value of DNA ploidy and c-erb B-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994;73(7):1785-94.
24. Launoy MC, Maurel J, Auvray S, Segol P, Gignoux M. Adenocarcinoma on endobrachyesophagus. Results and prognostic factors apropos of 19 cases surgically-treated. J Chir (Paris) 1992;129(4):187-90.
25. Kuwano H, Wantanabe M, Sadanaga N, Kamakura T, Nozoe T, Yasuda M, et al. Univariate and multivariate analyses of the prognostic significance of discontinuous intramural metastasis in patients with esophageal cancer. J Surg Oncol 1994;57:17-21.
26. Yoshinaka H, Shimazu H, Fukumoto T, Baba M. Superficial esophageal carcinoma: a clinicopathological review of 59 cases. Am J Gastroenterol 1991;86(10):1413-8.
27. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R. Impact of the Crohn's-like lymphoid reaction on staging of right sided colon cancer: results of multivariate analysis. Hum Pathol 1995;26:31-8.
28. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 1990;3:332-5.
29. Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
30. Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 1984;86:461-7.
31. Sarbia M, Bittinger F, Forschen R, Dutkowski P, Wilers R, Gabbert HE. Prognostic value of histopathologic parameters of esophageal squamous cell carcinoma. Cancer 1995;76(6): 922-7.
32. Edwards JM, Hillier VF, Lawson RAM, Mousalli H, Hasleton PS. Squamous carcinoma of the esophagus: histologic criteria and their prognostic significance. Br J Cancer 1989;59: 429-33.
33. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985;22:27-40.
34. Whiteside TL, Jost LM, Herberman RB. Tumor infiltrating lymphocytes: potential and limitations to their use for cancer therapy. Crit Rev Oncol Hematol 1992;20:25-47.
35. Koch B, Giedl J, Hermanek P, Kalden JR. The analysis of mononuclear cell infiltration in colorectal adenocarcinoma. J Cancer Res Clin Oncol 1985;109:142.
36. Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus: prognostic significance of histologic type. J Thorac Cardiovasc Surg 109(1):130-9.
37. Mahoney JL, Condon RE. Adenocarcinoma of the esophagus. Ann Surg 1987;205(5):557-62.
38. Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Cancer 1995;76(2): 178-86.
39. Turner JR, Shen LH, Crum CP, Dean PJ, Odze RD. Low prevalence of human papillomavirus infection in esophageal squamous cell carcinomas from North America: analysis by a highly sensitive and specific polymerase chain reaction-based approach. Hum Pathol 1997;28(2):174-8.
40. Keller SM, Coia LR, Ryan L, Dang P, Benson A. Chemoradiation followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 1995; 196A.